Drugs / AFM11
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02848911 | Oct 2016 → Sep 2018 | B-cell acute lymphoblastic leukemia | Affimed GmbH | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02106091 | Apr 2014 → Aug 2018 | B-cell non-Hodgkin lymphoma | Affimed GmbH | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AFM11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02106091 ↗ |
| Action | Deplete | “lead to the activation of T cells inducing apoptosis and killing of malignant B cells” PMID 36597128 ↗ Jan 2023 |
| Route | Intravenous | “IV (intravenous) infusion” NCT02106091 ↗ |